American Journal of Neuroradiology 28:830-834, May 2007
© 2007 American Society of Neuroradiology
INTERVENTIONAL
Apollo Stent for Symptomatic Atherosclerotic Intracranial Stenosis: Study Results
a Neurovascular Angioplasty Team, and the Departments of Neurology, Beijing Tiantan Hospital, the Capital University of Medical Sciences, Beijing, China
b Department of Neuroradiology, Beijing Tiantan Hospital, the Capital University of Medical Sciences, Beijing, China
c Interventional Neuroradiology, Beijing Tiantan Hospital, the Capital University of Medical Sciences, Beijing, China
Please address correspondence to Wei-Jian Jiang, MD, Department of Neurology and Interventional Neuroradiology, Beijing Tiantan Hospital, the Capital University of Medical Sciences, No. six Tiantan Xili, Beijing 100050, China; e-mail: cjr.jiangweijian{at}vip.163.com
BACKGROUND AND PURPOSE: A recent trial shows an 8.3 per 100-patient-years' ischemic stroke rate in the territory of the intracranial stenotic artery, despite aspirin treatment. Our aim was to prospectively study the feasibility and outcome of a new intracranial balloon-expandable Apollo stent for symptomatic atherosclerotic intracranial stenosis (SAIS).
MATERIALS AND METHODS: Forty-six patients (41 men and 5 women; median, 54 years of age) with forty-eight 
50% SAISs were enrolled. Procedural feasibility was evaluated by stent success (residual stenosis 
30%) and procedural time. The primary end point was ischemic stroke in the target-lesion artery territory, including any stroke and death within 30 days.
RESULTS: Forty-four lesions (91.7%) obtained stent success within a median procedural time of 50.6 minutes. Severe tortuosity correlated with stent failure. Three patients (6.5%, 3/46) had minor strokes within 30 days. All patients were available for follow-up (46 had 30-day follow-up, 45 had 6-month follow-up, 44 had 12- and 18-month follow-up, and 24 had follow-up of 24 months), which varied from 1 month to 30.7 months (median, 23.9 months). After 30 days, 1 patient (2.2%, 1/46) developed minor stroke in the target-lesion artery territory at 6.7 months. Primary end point rate was 4.3 per 100 patient years. Angiographic follow-up was performed in 25 patients. Seven restenoses (28%, 7/25) were detected, 1 of which was symptomatic.
CONCLUSION: Angioplasty with the Apollo stent for symptomatic atherosclerotic intracranial stenosis is feasible. Severe tortuosity is an independent predictor of stent failure. Our clinical outcome seems to compare favorably with results of aspirin therapy, but the restenotic rate was high.
This article has been cited by other articles:
 |
|
 |
|
  T. N. Turan, C. P. Derdeyn, D. Fiorella, and M. I. Chimowitz Treatment of Atherosclerotic Intracranial Arterial Stenosis Stroke, June 1, 2009; 40(6): 2257 - 2261. [Full Text] [PDF]
|
|
|
|
|
|
K. Groschel, S. Schnaudigel, S. M. Pilgram, K. Wasser, and A. Kastrup A Systematic Review on Outcome After Stenting for Intracranial Atherosclerosis Stroke, May 1, 2009; 40(5): e340 - e347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Siddiq, G. Vazquez, M. Z. Memon, M. F. K. Suri, R. A. Taylor, J. C. Wojak, J. C. Chaloupka, and A. I. Qureshi Comparison of Primary Angioplasty With Stent Placement for Treating Symptomatic Intracranial Atherosclerotic Diseases: A Multicenter Study Stroke, September 1, 2008; 39(9): 2505 - 2510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Puetz, G. Gahn, U. Becker, D. Mucha, A. Mueller, N.U. Weir, B. Wiedemann, and R. von Kummer Endovascular Therapy of Symptomatic Intracranial Stenosis in Patients With Impaired Regional Cerebral Blood Flow or Failure of Medical Therapy AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 273 - 280. [Abstract] [Full Text] [PDF]
|
|